SA519402076B1 - Novel phenyl derivatives - Google Patents
Novel phenyl derivativesInfo
- Publication number
- SA519402076B1 SA519402076B1 SA519402076A SA519402076A SA519402076B1 SA 519402076 B1 SA519402076 B1 SA 519402076B1 SA 519402076 A SA519402076 A SA 519402076A SA 519402076 A SA519402076 A SA 519402076A SA 519402076 B1 SA519402076 B1 SA 519402076B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- novel phenyl
- phenyl derivatives
- methyl
- diabetes
- novel
- Prior art date
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- LRJQZGXEGNOHBH-UHFFFAOYSA-N 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitroimidazole Chemical compound [N+](=O)([O-])C1=C(OCC2=CN=C(N2C)[N+](=O)[O-])C=CC(=C1)[N+](=O)[O-] LRJQZGXEGNOHBH-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003470 mitochondria Anatomy 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present application provides a novel phenyl derivative, 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof, which is useful for regulating mitochondria activity, reducing adiposity, treating diseases including diabetes and diabetes-associated complications.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762443244P | 2017-01-06 | 2017-01-06 | |
US201762581355P | 2017-11-03 | 2017-11-03 | |
US201762585326P | 2017-11-13 | 2017-11-13 | |
PCT/US2018/012491 WO2018129258A1 (en) | 2017-01-06 | 2018-01-05 | Novel phenyl derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
SA519402076B1 true SA519402076B1 (en) | 2022-04-19 |
Family
ID=61569353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA519402076A SA519402076B1 (en) | 2017-01-06 | 2019-07-07 | Novel phenyl derivatives |
Country Status (26)
Country | Link |
---|---|
US (4) | US10618875B2 (en) |
EP (2) | EP3565806B1 (en) |
JP (2) | JP7090088B2 (en) |
KR (1) | KR102579648B1 (en) |
CN (2) | CN110167918B (en) |
AU (1) | AU2018205811B2 (en) |
BR (1) | BR112019013371A2 (en) |
CA (1) | CA3047138C (en) |
CL (1) | CL2019001842A1 (en) |
CO (1) | CO2019006865A2 (en) |
DK (1) | DK3565806T3 (en) |
ES (1) | ES2913431T3 (en) |
GE (1) | GEP20217227B (en) |
IL (1) | IL267868B (en) |
LT (1) | LT3565806T (en) |
MX (1) | MX2019007745A (en) |
MY (1) | MY192778A (en) |
PE (1) | PE20191243A1 (en) |
PH (1) | PH12019501318A1 (en) |
PL (1) | PL3565806T3 (en) |
PT (1) | PT3565806T (en) |
SA (1) | SA519402076B1 (en) |
SI (1) | SI3565806T1 (en) |
UA (1) | UA124026C2 (en) |
WO (1) | WO2018129258A1 (en) |
ZA (1) | ZA201903808B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
ES2938341T3 (en) | 2016-03-07 | 2023-04-10 | Enanta Pharm Inc | Antiviral agents against hepatitis B |
EA202090514A1 (en) | 2017-08-28 | 2020-06-24 | Энанта Фармасьютикалс, Инк. | ANTI-VIRAL AGAINST HEPATITIS IN |
US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
US10865211B2 (en) | 2018-09-21 | 2020-12-15 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
KR20210093951A (en) | 2018-11-21 | 2021-07-28 | 이난타 파마슈티칼스, 인코포레이티드 | Functionalized Heterocycles as Antiviral Agents |
US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
CA3219548A1 (en) | 2021-05-20 | 2022-11-24 | Rivus Pharmaceuticals, Inc. | Methods of treating mitochondria-related disorders |
WO2023150767A1 (en) | 2022-02-07 | 2023-08-10 | Rivus Pharmaceuticals, Inc. | Methods of weight loss and preserving skeletal muscle mass |
WO2023150759A1 (en) | 2022-02-07 | 2023-08-10 | Rivus Pharmaceuticals, Inc. | Methods of weight loss in a subject with elevated hba1c |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3828056A (en) * | 1972-09-11 | 1974-08-06 | Searle & Co | (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers |
EG11928A (en) * | 1974-12-16 | 1979-03-31 | Hoechst Ag | Process for preparing of 1-alkyl-2-(phenoxy-methyl)-5-nitro-imidazoles |
US5359078A (en) * | 1989-05-19 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Signal transduction inhibitor compounds |
JP2006514101A (en) | 2002-11-08 | 2006-04-27 | ノボ・ノルデイスク・エー/エス | Safe chemical uncouplers for the treatment of obesity |
JP2007503453A (en) | 2003-05-14 | 2007-02-22 | ノボ ノルディスク アクティーゼルスカブ | Novel compounds for treating obesity |
EP1638943B1 (en) * | 2003-05-27 | 2008-08-06 | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) | Novel imidazole derivatives, the production thereof, and the use of the same as a medicament |
WO2005051900A1 (en) | 2003-11-25 | 2005-06-09 | Novo Nordisk A/S | Novel compounds for the treatment of obesity |
AU2004293133A1 (en) | 2003-11-25 | 2005-06-09 | High Point Pharmaceuticals, Llc | Novel salicylic anilides |
US20070010559A1 (en) | 2003-11-25 | 2007-01-11 | Novo Nordisk A/S | Indole derivatives for use as chemical uncoupler |
US8003625B2 (en) | 2005-06-29 | 2011-08-23 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
ES2377322T3 (en) | 2006-11-15 | 2012-03-26 | High Point Pharmaceuticals, Llc | New 2- (2-hydroxyphenyl) benzothiadiazines useful for the treatment of obesity and diabetes |
WO2008059023A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | New haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
US20100249161A1 (en) | 2006-11-15 | 2010-09-30 | Anders Klarskov Petersen | 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes |
WO2008059026A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
JP5765634B2 (en) | 2008-10-21 | 2015-08-19 | スレッシュホールド ファーマシューティカルズ, インコーポレイテッド | Treatment of cancer with hypoxia activated prodrugs |
EP2179984A1 (en) * | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
CN101560189B (en) * | 2009-05-20 | 2011-02-16 | 南京大学 | Metronidazole and compound for substituting salicylic acid and preparation method and application thereof |
WO2011162633A1 (en) | 2010-06-24 | 2011-12-29 | Общество С Ограниченной Ответственностью "Mиtotex" | Soft cationic mitochondrial uncouplers |
ES2784223T3 (en) | 2012-06-20 | 2020-09-23 | Univ Virginia Patent Foundation | Compositions and procedures for regulating glucose homeostasis and insulin action |
JP6706204B2 (en) | 2013-08-30 | 2020-06-03 | イエール ユニバーシティ | Novel 2,4-dinitrophenol preparation and its use |
US10457629B2 (en) | 2013-08-30 | 2019-10-29 | Yale University | Therapeutic DNP derivatives and methods using same |
CA2954004C (en) | 2014-07-03 | 2023-10-10 | NAN Global, LLC | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes |
US20160008298A1 (en) * | 2014-07-14 | 2016-01-14 | Oregon State University | Xanthohumol-based compounds and compositions thereof, and methods of making and using the same |
EP3247340B1 (en) | 2015-01-22 | 2023-08-02 | Mitochon Pharmaceuticals, Inc. | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular and/or neurodegenerative diseases |
TWI794161B (en) | 2016-03-07 | 2023-03-01 | 美商米托控製藥公司 | Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss, and/or metabolic diseases |
US11896591B2 (en) | 2017-05-22 | 2024-02-13 | University Of Virginia Patent Foundation | Compositions and methods for preparing and using mitochondrial uncouplers |
-
2018
- 2018-01-05 AU AU2018205811A patent/AU2018205811B2/en active Active
- 2018-01-05 PL PL18709129T patent/PL3565806T3/en unknown
- 2018-01-05 DK DK18709129.3T patent/DK3565806T3/en active
- 2018-01-05 ES ES18709129T patent/ES2913431T3/en active Active
- 2018-01-05 GE GEAP201815132A patent/GEP20217227B/en unknown
- 2018-01-05 CN CN201880005988.7A patent/CN110167918B/en active Active
- 2018-01-05 WO PCT/US2018/012491 patent/WO2018129258A1/en unknown
- 2018-01-05 PE PE2019001339A patent/PE20191243A1/en unknown
- 2018-01-05 MY MYPI2019003195A patent/MY192778A/en unknown
- 2018-01-05 CA CA3047138A patent/CA3047138C/en active Active
- 2018-01-05 US US16/475,390 patent/US10618875B2/en active Active
- 2018-01-05 UA UAA201906673A patent/UA124026C2/en unknown
- 2018-01-05 EP EP18709129.3A patent/EP3565806B1/en active Active
- 2018-01-05 CN CN202310980210.0A patent/CN117024351A/en active Pending
- 2018-01-05 BR BR112019013371A patent/BR112019013371A2/en active Search and Examination
- 2018-01-05 JP JP2019537086A patent/JP7090088B2/en active Active
- 2018-01-05 SI SI201830676T patent/SI3565806T1/en unknown
- 2018-01-05 LT LTEPPCT/US2018/012491T patent/LT3565806T/en unknown
- 2018-01-05 MX MX2019007745A patent/MX2019007745A/en unknown
- 2018-01-05 PT PT187091293T patent/PT3565806T/en unknown
- 2018-01-05 KR KR1020197018983A patent/KR102579648B1/en active IP Right Grant
- 2018-01-05 EP EP22157494.0A patent/EP4086242A1/en active Pending
-
2019
- 2019-06-11 PH PH12019501318A patent/PH12019501318A1/en unknown
- 2019-06-12 ZA ZA2019/03808A patent/ZA201903808B/en unknown
- 2019-06-27 CO CONC2019/0006865A patent/CO2019006865A2/en unknown
- 2019-07-03 CL CL2019001842A patent/CL2019001842A1/en unknown
- 2019-07-04 IL IL267868A patent/IL267868B/en unknown
- 2019-07-07 SA SA519402076A patent/SA519402076B1/en unknown
-
2020
- 2020-09-02 US US17/010,547 patent/US20200399225A1/en not_active Abandoned
-
2021
- 2021-04-15 US US17/231,168 patent/US20210238144A1/en active Pending
- 2021-10-28 US US17/513,235 patent/US20220048865A1/en not_active Abandoned
-
2022
- 2022-06-13 JP JP2022095049A patent/JP2022120118A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA519402076B1 (en) | Novel phenyl derivatives | |
MX2023001517A (en) | Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof. | |
PH12019502345A1 (en) | Methods of treatment using a jak inhibitor compoud | |
PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
PH12017550004A1 (en) | Heterocyclic derivatives and use thereof | |
MX367554B (en) | Heterocyclic derivatives and use thereof. | |
MX2022006663A (en) | Oxygen-containing heterocyclic compound, preparation method and application thereof. | |
BR112012004851B8 (en) | use of a thiazole derivative | |
MX2022001697A (en) | Pyrrolopyridine-aniline compounds for treatment of dermal disorders. | |
NZ603490A (en) | Fungicidal composition and method for controlling plant diseases | |
UA114822C2 (en) | Active compound combinations comprising carboxamide derivatives | |
WO2018153508A3 (en) | Sulfoximine glycosidase inhibitors | |
TW201713650A (en) | NADPH oxidase 4 inhibitors | |
NZ719688A (en) | Pesticidal compositions and related methods | |
MX2022003270A (en) | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof. | |
PH12020550649A1 (en) | Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds | |
PH12020551700A1 (en) | Heterocyclene derivatives as pest control agents | |
PH12020550733A1 (en) | Nitrogenous heterocycles as a pesticide | |
MX2012002529A (en) | Therapeutic agent for anxiety disorders. | |
MX2022004713A (en) | Thiophene derivatives as xanthine oxidase inhibitors and application thereof. | |
EA201991180A1 (en) | NEW FENILY DERIVATIVES | |
MX2016011310A (en) | Endoparasite control agent. | |
MX2020000752A (en) | Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue. | |
MX2020007627A (en) | Use of carrimycin or active ingredient thereof. | |
MX2019002104A (en) | 3-pyridyloxyphenyldihydrouracil compound and use thereof. |